| NCT03828448 |
Study to Assess Umbralisib Plus Ublituximab in Patients With Treatment Naïve Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT03828448 |
Recruiting |
TG Therapeutics, Inc. |
2022-02-28 |
| NCT03789240 |
Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT03789240 |
Recruiting |
National Institutes of Health Clinical Center (CC) |
2027-01-01 |
| NCT03768505 |
ME-401 in Subjects With Follicular Lymphoma After Failure of Two or More Prior Therapies (TIDAL) |
https://ClinicalTrials.gov/show/NCT03768505 |
Recruiting |
MEI Pharma, Inc. |
2020-12-31 |
| NCT03410901 |
TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas |
https://ClinicalTrials.gov/show/NCT03410901 |
Recruiting |
Stanford University |
2020-10-09 |
| NCT03401853 |
Rituximab and Pembrolizumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03401853 |
Recruiting |
University of Washington |
2021-02-15 |
| NCT03381768 |
Peptide Vaccination Against PD-L1 and PD-L2 in Relapsed Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT03381768 |
Active, not recruiting |
Herlev Hospital |
2020-12-31 |
| NCT03341520 |
Gazyvaro and Low Dose Radiotherapy in Early Stage Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT03341520 |
Recruiting |
Heidelberg University |
2021-06-30 |
| NCT03310619 |
A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies (PLATFORM) |
https://ClinicalTrials.gov/show/NCT03310619 |
Recruiting |
Celgene |
2023-04-11 |
| NCT03297424 |
A Study of PLX2853 in Advanced Malignancies. |
https://ClinicalTrials.gov/show/NCT03297424 |
Recruiting |
Plexxikon |
2020-12-31 |
| NCT03277729 |
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas |
https://ClinicalTrials.gov/show/NCT03277729 |
Recruiting |
Fred Hutchinson Cancer Research Center |
2022-11-16 |
| NCT03245021 |
Nivolumab Plus Rituximab in First-line Follicular Lymphoma gr 1-3A |
https://ClinicalTrials.gov/show/NCT03245021 |
Recruiting |
Austin Health |
2022-06-30 |
| NCT03238651 |
A Study of TAK-659 as a Single Agent in Adult East Asian Participants With Non-Hodgkin Lymphoma (NHL) |
https://ClinicalTrials.gov/show/NCT03238651 |
Active, not recruiting |
Takeda |
2020-10-09 |
| NCT03185494 |
Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22 |
https://ClinicalTrials.gov/show/NCT03185494 |
Active, not recruiting |
Chinese PLA General Hospital |
2019-08-01 |
| NCT03178201 |
TGR1202 in Relapsed and Refractory Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT03178201 |
Recruiting |
Columbia University |
2020-05-31 |
| NCT03269669 |
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT03269669 |
Recruiting |
National Cancer Institute (NCI) |
2022-12-31 |
| NCT03162536 |
A Study of ARQ 531 in Patients With Selected Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT03162536 |
Recruiting |
ArQule |
2021-12-31 |
| NCT03150329 |
Pembrolizumab and Vorinostat in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, or Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT03150329 |
Recruiting |
City of Hope Medical Center |
2020-07-18 |
| NCT03147885 |
Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT03147885 |
Recruiting |
Barbara Ann Karmanos Cancer Institute |
2020-06-30 |
| NCT03126019 |
An Open-Label Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma (CITADEL-203) |
https://ClinicalTrials.gov/show/NCT03126019 |
Recruiting |
Incyte Corporation |
2020-10-31 |
| NCT03121677 |
Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT03121677 |
Recruiting |
Washington University School of Medicine |
2022-07-31 |
| NCT03113422 |
Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy |
https://ClinicalTrials.gov/show/NCT03113422 |
Recruiting |
PrECOG, LLC. |
2022-04-30 |
| NCT03097770 |
Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20 |
https://ClinicalTrials.gov/show/NCT03097770 |
Recruiting |
Chinese PLA General Hospital |
2019-05-10 |
| NCT03069248 |
Treatment of Follicular Lymphoma With High Dose Therapy and Stem Cell Support Followed by Rituximab and Alpha Interferon |
https://ClinicalTrials.gov/show/NCT03069248 |
Completed |
Sunnybrook Health Sciences Centre |
2009-09-17 |
| NCT03057418 |
Open-label Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AuriÑ…im |
https://ClinicalTrials.gov/show/NCT03057418 |
Completed |
Biointegrator LLC |
2016-12-31 |
| NCT03039114 |
Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102) |
https://ClinicalTrials.gov/show/NCT03039114 |
Active, not recruiting |
Incyte Corporation |
2021-09-30 |
| NCT03037645 |
Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers |
https://ClinicalTrials.gov/show/NCT03037645 |
Recruiting |
Sunesis Pharmaceuticals |
2020-12-31 |
| NCT03019640 |
Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT03019640 |
Recruiting |
M.D. Anderson Cancer Center |
2020-03-31 |
| NCT03015896 |
Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT03015896 |
Recruiting |
Ohio State University Comprehensive Cancer Center |
2020-04-30 |
| NCT03010358 |
Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT03010358 |
Active, not recruiting |
OHSU Knight Cancer Institute |
2022-02-28 |
| NCT02996773 |
Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine |
https://ClinicalTrials.gov/show/NCT02996773 |
Recruiting |
University of Arizona |
2022-11-29 |
| NCT02950220 |
Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT02950220 |
Completed |
Ohio State University Comprehensive Cancer Center |
2018-11-19 |
| NCT02947347 |
Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT02947347 |
Recruiting |
Pharmacyclics LLC. |
2022-01-31 |
| NCT02877550 |
Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients |
https://ClinicalTrials.gov/show/NCT02877550 |
Active, not recruiting |
Swiss Group for Clinical Cancer Research |
2021-06-30 |
| NCT02871219 |
Obinutuzumab and Lenalidomide in Treating Patients With Previously Untreated Stage II-IV Grade 1-3a Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT02871219 |
Active, not recruiting |
M.D. Anderson Cancer Center |
2023-07-23 |
| NCT02869633 |
Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT02869633 |
Active, not recruiting |
Vanderbilt-Ingram Cancer Center |
2021-10-31 |
| NCT02797470 |
Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT02797470 |
Recruiting |
AIDS Malignancy Consortium |
2021-09-30 |
| NCT02756247 |
A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma |
https://ClinicalTrials.gov/show/NCT02756247 |
Active, not recruiting |
Memorial Sloan Kettering Cancer Center |
2021-05-31 |
| NCT02729896 |
A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) |
https://ClinicalTrials.gov/show/NCT02729896 |
Completed |
Hoffmann-La Roche |
2018-09-03 |
| NCT02723071 |
A Study of Ocrelizumab in Participants With Follicular Non-Hodgkin’s Lymphoma (NHL) |
https://ClinicalTrials.gov/show/NCT02723071 |
Completed |
Hoffmann-La Roche |
2008-01-31 |
| NCT02710643 |
“MIRO” Molecularly Oriented Immuno-radio-therapy |
https://ClinicalTrials.gov/show/NCT02710643 |
Active, not recruiting |
Fondazione Italiana Linfomi ONLUS |
2018-04-30 |
| NCT02689869 |
Combination of PCI-32765 With Obinutuzumab in Untreated Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT02689869 |
Active, not recruiting |
Ludwig-Maximilians - University of Munich |
2022-04-30 |
| NCT02677155 |
Sequential Intranodal Immunotherapy (SIIT) Combined With Anti-PD1 (Pembrolizumab) in Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT02677155 |
Recruiting |
Oslo University Hospital |
2020-01-31 |
| NCT02669017 |
Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL) |
https://ClinicalTrials.gov/show/NCT02669017 |
Completed |
ADC Therapeutics S.A. |
2019-02-21 |
| NCT02652715 |
Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT02652715 |
Completed |
Mayo Clinic |
2018-12-21 |
| NCT02631577 |
A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT02631577 |
Active, not recruiting |
Hoffmann-La Roche |
2018-10-23 |
| NCT02611323 |
A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL) |
https://ClinicalTrials.gov/show/NCT02611323 |
Active, not recruiting |
Hoffmann-La Roche |
2020-09-08 |
| NCT02603445 |
Study of Safety and Efficacy of BCL201 and Idelalisib in Patients With FL and MCL |
https://ClinicalTrials.gov/show/NCT02603445 |
Completed |
Novartis |
2018-07-10 |
| NCT02600897 |
A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) |
https://ClinicalTrials.gov/show/NCT02600897 |
Active, not recruiting |
Hoffmann-La Roche |
2020-10-05 |
| NCT02596971 |
A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) |
https://ClinicalTrials.gov/show/NCT02596971 |
Active, not recruiting |
Hoffmann-La Roche |
2018-04-11 |
| NCT03357627 |
A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT03357627 |
Active, not recruiting |
Takeda |
2020-10-28 |
| NCT02956382 |
Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT02956382 |
Recruiting |
Georgetown University |
2020-11-30 |
| NCT02927964 |
TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT02927964 |
Recruiting |
Stanford University |
2021-11-30 |
| NCT02376699 |
Safety Study of SEA-CD40 in Cancer Patients |
https://ClinicalTrials.gov/show/NCT02376699 |
Recruiting |
Seattle Genetics, Inc. |
2021-10-31 |
| NCT02569996 |
A Study of Long-Term Rituximab (MabThera) Maintenance Therapy in Participants With Advanced Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT02569996 |
Completed |
Hoffmann-La Roche |
2013-08-31 |
| NCT02568553 |
Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT02568553 |
Recruiting |
National Cancer Institute (NCI) |
2020-12-31 |
| NCT01381692 |
Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT01381692 |
Active, not recruiting |
National Cancer Institute (NCI) |
2014-07-23 |
| NCT02541565 |
Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT02541565 |
Completed |
University of Washington |
2018-12-18 |
| NCT02536300 |
Dose Optimization Study of Idelalisib in Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT02536300 |
Recruiting |
Gilead Sciences |
2025-11-30 |
| NCT02532257 |
Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma |
https://ClinicalTrials.gov/show/NCT02532257 |
Active, not recruiting |
M.D. Anderson Cancer Center |
2020-04-01 |
| NCT02520791 |
Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT02520791 |
Recruiting |
National Cancer Institute (NCI) |
2020-12-31 |
| NCT02494700 |
Ultra Low Dose Orbital Radiation Therapy in Treating Patients With Stage I-IV Indolent B-cell Lymphoma or Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT02494700 |
Recruiting |
M.D. Anderson Cancer Center |
2021-10-31 |
| NCT02449252 |
Efficacy of Consolidative Involved-site Radiotherapy for Patients With Limited-stage Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT02449252 |
Recruiting |
Wuhan University |
2019-10-31 |
| NCT02446457 |
Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT02446457 |
Recruiting |
M.D. Anderson Cancer Center |
2021-11-01 |
| NCT02438501 |
Efficacy of Palliative Low-Dose Involved-Field Radiation Therapy for Recurrent Advanced Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT02438501 |
Recruiting |
Wuhan University |
2019-10-31 |
| NCT02432235 |
Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT02432235 |
Completed |
ADC Therapeutics S.A. |
2019-10-24 |
| NCT02423837 |
Bendamustine in Combination With Rituximab as a First-line Therapy Followed by Maintenance Therapy With Rituximab in Patients With Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT02423837 |
Recruiting |
National Research Center for Hematology, Russia |
2016-02-29 |
| NCT02390869 |
Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients |
https://ClinicalTrials.gov/show/NCT02390869 |
Recruiting |
Fondazione Italiana Linfomi ONLUS |
2022-12-31 |
| NCT02343536 |
A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed Lymphoma |
https://ClinicalTrials.gov/show/NCT02343536 |
Active, not recruiting |
Celgene |
2020-02-01 |
| NCT02332980 |
Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas |
https://ClinicalTrials.gov/show/NCT02332980 |
Recruiting |
Mayo Clinic |
2021-01-05 |
| NCT02320292 |
Rituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT02320292 |
Recruiting |
Mayo Clinic |
2020-06-01 |
| NCT02303119 |
Follicular Lymphoma IV/SC Rituximab Therapy (FLIRT) |
https://ClinicalTrials.gov/show/NCT02303119 |
Active, not recruiting |
The Lymphoma Academic Research Organisation |
2020-06-30 |
| NCT02282358 |
Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT02282358 |
Active, not recruiting |
Memorial Sloan Kettering Cancer Center |
2021-10-31 |
| NCT02257242 |
Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab—Phase I Trial in Indolent B-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT02257242 |
Recruiting |
Brown University |
2020-12-31 |
| NCT02254772 |
A Phase I/II Study of Intratumoral Injection of SD-101 |
https://ClinicalTrials.gov/show/NCT02254772 |
Completed |
Stanford University |
2016-11-10 |
| NCT02240719 |
Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT02240719 |
Completed |
University of California, Davis |
2018-04-09 |
| NCT02220842 |
A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT02220842 |
Completed |
Hoffmann-La Roche |
2020-01-21 |
| NCT02216890 |
Safety Study of SGN-CD70A in Cancer Patients |
https://ClinicalTrials.gov/show/NCT02216890 |
Completed |
Seattle Genetics, Inc. |
2017-02-15 |
| NCT02213913 |
Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas |
https://ClinicalTrials.gov/show/NCT02213913 |
Recruiting |
University of Chicago |
2020-07-29 |
| NCT02213263 |
A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06) |
https://ClinicalTrials.gov/show/NCT02213263 |
Completed |
Pfizer |
2017-10-23 |
| NCT02208037 |
Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) |
https://ClinicalTrials.gov/show/NCT02208037 |
Completed |
National Heart, Lung, and Blood Institute (NHLBI) |
2017-10-31 |
| NCT02187861 |
A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin’s Lymphoma (fNHL) |
https://ClinicalTrials.gov/show/NCT02187861 |
Completed |
Hoffmann-La Roche |
2016-09-27 |
| NCT02162771 |
To Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan |
https://ClinicalTrials.gov/show/NCT02162771 |
Completed |
Celltrion |
2016-01-12 |
| NCT02153580 |
Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia or B-Cell Prolymphocytic Leukemia |
https://ClinicalTrials.gov/show/NCT02153580 |
Recruiting |
City of Hope Medical Center |
2021-12-31 |
| NCT02063685 |
Study to Evaluate the Efficacy of Response-adapted Strategy in Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT02063685 |
Active, not recruiting |
Fondazione Italiana Linfomi ONLUS |
2021-12-31 |
| NCT01307605 |
Rituximab With or Without Lenalidomide in Treating Patients With Previously Untreated Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT01307605 |
Active, not recruiting |
Swiss Group for Clinical Cancer Research |
2014-06-20 |
| NCT01307267 |
A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab |
https://ClinicalTrials.gov/show/NCT01307267 |
Completed |
Pfizer |
2019-02-20 |
| NCT01306643 |
Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma |
https://ClinicalTrials.gov/show/NCT01306643 |
Completed |
Gilead Sciences |
2015-08-31 |
| NCT01286272 |
Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01286272 |
Active, not recruiting |
National Cancer Institute (NCI) |
2017-05-24 |
| NCT01282424 |
Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas |
https://ClinicalTrials.gov/show/NCT01282424 |
Completed |
Gilead Sciences |
2018-05-02 |
| NCT01275209 |
Study of HCD122 (Lucatumumab) and Bendamustine Combination Therapy in CD40+ Rituximab-refractory Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT01275209 |
Completed |
Novartis |
2012-05-31 |
| NCT01273766 |
Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01273766 |
Completed |
Wake Forest University Health Sciences |
2012-03-31 |
| NCT02049541 |
Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT02049541 |
Active, not recruiting |
Ohio State University Comprehensive Cancer Center |
2018-09-12 |
| NCT02038946 |
Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140) |
https://ClinicalTrials.gov/show/NCT02038946 |
Active, not recruiting |
Bristol-Myers Squibb |
2017-05-17 |
| NCT02031419 |
Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT02031419 |
Active, not recruiting |
Celgene |
2020-11-30 |
| NCT04324879 |
A Study of TQ-B3525 in the Treatment of Relapsed / Refractory Follicular Lymphoma (FL) |
https://ClinicalTrials.gov/show/NCT04324879 |
Recruiting |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2022-12-31 |
| NCT03479268 |
Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT03479268 |
Recruiting |
City of Hope Medical Center |
2022-04-01 |
| NCT02012088 |
Clinical Trial to Evaluate R-COMP Versus R-CHOP in Newly Diagnosed Patients With Non-localised Diffuse Large B-cell Lymphoma (DLBCL)/Follicular Lymphoma Grade IIIb |
https://ClinicalTrials.gov/show/NCT02012088 |
Active, not recruiting |
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea |
2016-10-31 |
| NCT01995669 |
Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01995669 |
Active, not recruiting |
M.D. Anderson Cancer Center |
2021-05-31 |
| NCT01980654 |
Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT01980654 |
Completed |
Pharmacyclics LLC. |
2017-11-30 |
| NCT01962636 |
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases |
https://ClinicalTrials.gov/show/NCT01962636 |
Recruiting |
Masonic Cancer Center, University of Minnesota |
2023-10-31 |
| NCT01959477 |
Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT01959477 |
Completed |
Case Comprehensive Cancer Center |
2015-01-31 |
| NCT01955499 |
Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01955499 |
Active, not recruiting |
National Cancer Institute (NCI) |
2021-12-31 |
| NCT01950273 |
Pharmacokinetics and Pharmacodynamics of BI 695500 vs. Rituximab as First Line-treatment in Patients With Low Tumor Burden Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT01950273 |
Completed |
Boehringer Ingelheim |
2015-12-22 |
| NCT01939899 |
Phase 2 Study of Oral IXAZOMIB in Adult Participants With Relapsed and/or Refractory Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT01939899 |
Completed |
Takeda |
2016-06-01 |
| NCT01926639 |
Phase II Cancer Vaccine Trial for Patients With Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT01926639 |
Completed |
Oslo University Hospital |
2014-10-31 |
| NCT01897571 |
Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Adv. Solid Tumors or With B-cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With DLBCL |
https://ClinicalTrials.gov/show/NCT01897571 |
Active, not recruiting |
Epizyme, Inc. |
2019-11-30 |
| NCT01897012 |
Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas |
https://ClinicalTrials.gov/show/NCT01897012 |
Completed |
National Cancer Institute (NCI) |
2018-10-31 |
| NCT01889069 |
A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) |
https://ClinicalTrials.gov/show/NCT01889069 |
Completed |
Hoffmann-La Roche |
2019-05-28 |
| NCT01839916 |
Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01839916 |
Completed |
University of Chicago |
2018-08-31 |
| NCT01830465 |
VELCADE® Plus Rituximab in Non Hodgkin’s Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT01830465 |
Completed |
Gruppo Italiano Studio Linfomi |
2008-08-31 |
| NCT01829568 |
Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT01829568 |
Active, not recruiting |
National Cancer Institute (NCI) |
2015-05-11 |
| NCT01827605 |
A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL) |
https://ClinicalTrials.gov/show/NCT01827605 |
Active, not recruiting |
Fondazione Italiana Linfomi ONLUS |
2020-06-30 |
| NCT01815749 |
Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01815749 |
Active, not recruiting |
City of Hope Medical Center |
2020-10-31 |
| NCT01805037 |
Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas |
https://ClinicalTrials.gov/show/NCT01805037 |
Active, not recruiting |
Northwestern University |
2021-01-31 |
| NCT01804686 |
A Long-term Extension Study of PCI-32765 (Ibrutinib) |
https://ClinicalTrials.gov/show/NCT01804686 |
Enrolling by invitation |
Janssen Research & Development, LLC |
2026-12-31 |
| NCT01789255 |
Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT01789255 |
Completed |
National Cancer Institute (NCI) |
2014-03-31 |
| NCT01786135 |
A Safety Study of SGN-CD19A for B-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01786135 |
Completed |
Seattle Genetics, Inc. |
2015-08-31 |
| NCT01779791 |
A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT01779791 |
Completed |
Janssen Research & Development, LLC |
2016-05-18 |
| NCT01760655 |
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01760655 |
Recruiting |
Thomas Jefferson University |
2021-03-31 |
| NCT01748721 |
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma |
https://ClinicalTrials.gov/show/NCT01748721 |
Completed |
Morphotek |
2015-05-31 |
| NCT01724021 |
A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin’s Lymphoma Grades 1, 2 or 3a |
https://ClinicalTrials.gov/show/NCT01724021 |
Completed |
Hoffmann-La Roche |
2015-01-31 |
| NCT01701232 |
Safety and Efficacy Study of BCD-020 in Therapy of Indolent Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT01701232 |
Completed |
Biocad |
2017-01-31 |
| NCT01693614 |
Safety and Efficacy of BKM120 in Relapsed and Refractory NHL |
https://ClinicalTrials.gov/show/NCT01693614 |
Completed |
Novartis |
2017-07-21 |
| NCT01682044 |
Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma |
https://ClinicalTrials.gov/show/NCT01682044 |
Completed |
Roswell Park Cancer Institute |
2013-11-22 |
| NCT01680991 |
A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease |
https://ClinicalTrials.gov/show/NCT01680991 |
Completed |
Hoffmann-La Roche |
2014-12-31 |
| NCT01678443 |
Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies |
https://ClinicalTrials.gov/show/NCT01678443 |
Active, not recruiting |
Fred Hutchinson Cancer Research Center |
2011-04-11 |
| NCT01658319 |
Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01658319 |
Completed |
Case Comprehensive Cancer Center |
2015-02-28 |
| NCT01650701 |
A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT01650701 |
Active, not recruiting |
The Lymphoma Academic Research Organisation |
2023-12-31 |
| NCT01644799 |
Lenalidomide and Idelalisib in Treating Patients With Recurrent Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT01644799 |
Completed |
Alliance for Clinical Trials in Oncology |
2014-08-31 |
| NCT01588015 |
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT01588015 |
Active, not recruiting |
City of Hope Medical Center |
2021-11-30 |
| NCT01567709 |
Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01567709 |
Completed |
National Cancer Institute (NCI) |
2018-03-29 |
| NCT01529827 |
Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01529827 |
Completed |
Roswell Park Cancer Institute |
2015-05-28 |
| NCT01523860 |
Brief Chemoimmunotherapy With R+B+M Followed by R in Elderly Patients Advanced Stage Untreated Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT01523860 |
Completed |
Fondazione Italiana Linfomi ONLUS |
2015-01-31 |
| NCT01523223 |
Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies |
https://ClinicalTrials.gov/show/NCT01523223 |
Completed |
Stanford University |
2016-09-30 |
| NCT01493479 |
Phase II Study of Fractionated 90Y Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy as an Initial Therapy of Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT01493479 |
Completed |
The Christie NHS Foundation Trust |
2011-01-31 |
| NCT01484015 |
Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia |
https://ClinicalTrials.gov/show/NCT01484015 |
Completed |
Wake Forest University Health Sciences |
2012-06-30 |
| NCT01479842 |
Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT01479842 |
Active, not recruiting |
Ohio State University Comprehensive Cancer Center |
2014-03-31 |
| NCT01473628 |
Radiation Therapy and Rituximab in Treating Patients With Stage I-II Grade 1 or Grade 2 Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT01473628 |
Recruiting |
M.D. Anderson Cancer Center |
2027-05-20 |
| NCT01446562 |
Y90 Ibritumomab Tiuxetan Post R-CHOP Chemotherapy for Advanced Stage Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT01446562 |
Completed |
Sunnybrook Health Sciences Centre |
2016-05-31 |
| NCT01419665 |
GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT01419665 |
Completed |
Sandoz |
2015-07-10 |
| NCT01393756 |
Revlimid Dose 25 mg in Association With (R-CHOP) in the Treatment Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT01393756 |
Completed |
The Lymphoma Academic Research Organisation |
2013-07-31 |
| NCT01392716 |
A Study of MabThera/Rituxan (Rituximab) in Patients With Non-Bulky Follicular Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT01392716 |
Completed |
Hoffmann-La Roche |
2006-02-28 |
| NCT01388959 |
A Study of MabThera/Rituxan (Rituximab) in Patients With Follicular Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT01388959 |
Completed |
Hoffmann-La Roche |
2004-04-30 |
| NCT01384513 |
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT01384513 |
Recruiting |
Thomas Jefferson University |
2020-12-31 |
| NCT01326702 |
Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors |
https://ClinicalTrials.gov/show/NCT01326702 |
Completed |
National Cancer Institute (NCI) |
2015-04-30 |
| NCT01321541 |
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT01321541 |
Completed |
CTI BioPharma |
2018-06-28 |
| NCT04370405 |
A Study of YY-20394 in Participants With Relapsed/Refractory Follicular Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT04370405 |
Recruiting |
Shanghai YingLi Pharmaceutical Co. Ltd. |
2020-11-30 |
| NCT04323956 |
Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT04323956 |
Recruiting |
Mayo Clinic |
2026-05-15 |
| NCT04305444 |
Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin’s Lymphomas |
https://ClinicalTrials.gov/show/NCT04305444 |
Recruiting |
Zhejiang DTRM Biopharma |
2022-03-31 |
| NCT04298879 |
IBI376 in Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma |
https://ClinicalTrials.gov/show/NCT04298879 |
Recruiting |
Innovent Biologics (Suzhou) Co. Ltd. |
2021-07-31 |
| NCT04205838 |
Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT04205838 |
Recruiting |
Jonsson Comprehensive Cancer Center |
2021-12-01 |
| NCT04205409 |
Nivolumab for Relapsed or Refractory Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT04205409 |
Recruiting |
University of Washington |
2022-08-01 |
| NCT04156828 |
Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT04156828 |
Recruiting |
University of Washington |
2022-07-31 |
| NCT04097067 |
ISRT 20 Gy for Indolent Localized Gastrointestinal (GI)-Lymphoma |
https://ClinicalTrials.gov/show/NCT04097067 |
Recruiting |
University Hospital Muenster |
2021-08-31 |
| NCT04082936 |
A Safety and Pharmacokinetic Study of IGM-2323 in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT04082936 |
Recruiting |
IGM Biosciences, Inc. |
2021-09-30 |
| NCT04049513 |
ENABLE (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy) |
https://ClinicalTrials.gov/show/NCT04049513 |
Recruiting |
Malaghan Institute of Medical Research |
2021-09-30 |
| NCT04007029 |
Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia |
https://ClinicalTrials.gov/show/NCT04007029 |
Recruiting |
Jonsson Comprehensive Cancer Center |
2022-08-01 |
| NCT03999697 |
A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies |
https://ClinicalTrials.gov/show/NCT03999697 |
Recruiting |
PersonGen BioTherapeutics (Suzhou) Co., Ltd. |
2020-12-01 |
| NCT03980171 |
Study of Lenalidomide, Venetoclax and Obinutuzumab in Patients With Treatment-Naïve Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT03980171 |
Recruiting |
Peter MacCallum Cancer Centre, Australia |
2026-11-30 |
| NCT03939026 |
Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT03939026 |
Recruiting |
Allogene Therapeutics |
2021-10-31 |
| NCT03934567 |
A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT03934567 |
Recruiting |
Xynomic Pharmaceuticals, Inc. |
2023-06-30 |
| NCT03921879 |
Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma |
https://ClinicalTrials.gov/show/NCT03921879 |
Recruiting |
Oncotartis, Inc. |
2021-04-30 |
| NCT03919175 |
Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma |
https://ClinicalTrials.gov/show/NCT03919175 |
Recruiting |
Massachusetts General Hospital |
2022-11-30 |
| NCT03892044 |
Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT03892044 |
Recruiting |
Ohio State University Comprehensive Cancer Center |
2021-12-31 |
| NCT03817853 |
An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT03817853 |
Recruiting |
Hoffmann-La Roche |
2020-07-20 |
| NCT03806179 |
Study of Safety and Efficacy of Betalutin and Rituximab in Patients With FL |
https://ClinicalTrials.gov/show/NCT03806179 |
Recruiting |
Nordic Nanovector |
2020-09-30 |
| NCT03720457 |
Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory CD19-positive Lymphoma. |
https://ClinicalTrials.gov/show/NCT03720457 |
Recruiting |
Hrain Biotechnology Co., Ltd. |
2021-10-31 |
| NCT03715309 |
R2 in the Treatment of Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT03715309 |
Recruiting |
Ruijin Hospital |
2020-11-01 |
| NCT03685344 |
Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT03685344 |
Active, not recruiting |
ADC Therapeutics S.A. |
2021-01-29 |
| NCT03682796 |
Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03682796 |
Recruiting |
Triphase Research and Development III Corp. |
2022-01-31 |
| NCT03636503 |
RITUXIMAB + IMMUNOTHERAPY IN FOLLICULAR LYMPHOMA |
https://ClinicalTrials.gov/show/NCT03636503 |
Recruiting |
Dana-Farber Cancer Institute |
2021-10-30 |
| NCT03610061 |
A Trial of Radiotherapy and Durvalumab in DLBCL and FL |
https://ClinicalTrials.gov/show/NCT03610061 |
Recruiting |
Austin Health |
2021-02-28 |
| NCT03600441 |
Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT03600441 |
Active, not recruiting |
Xynomic Pharmaceuticals, Inc. |
2020-09-01 |
| NCT03600363 |
A Clinical Trial of Metformin in the Maintenance of Non-Hodgkin’s Lymphoma Patients |
https://ClinicalTrials.gov/show/NCT03600363 |
Recruiting |
Ruijin Hospital |
2021-01-31 |
| NCT03598998 |
Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas |
https://ClinicalTrials.gov/show/NCT03598998 |
Recruiting |
City of Hope Medical Center |
2021-04-27 |
| NCT03583424 |
Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT03583424 |
Recruiting |
Ohio State University Comprehensive Cancer Center |
2021-12-31 |
| NCT03571828 |
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT03571828 |
Recruiting |
Amgen |
2023-06-30 |
| NCT03568461 |
Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT03568461 |
Active, not recruiting |
Novartis |
2021-02-22 |
| NCT01261247 |
Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01261247 |
Active, not recruiting |
Mayo Clinic |
2016-05-09 |
| NCT01258998 |
Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma |
https://ClinicalTrials.gov/show/NCT01258998 |
Completed |
National Cancer Institute (NCI) |
2014-07-31 |
| NCT01254578 |
Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers |
https://ClinicalTrials.gov/show/NCT01254578 |
Completed |
National Cancer Institute (NCI) |
2012-11-09 |
| NCT01239875 |
Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01239875 |
Completed |
Mayo Clinic |
2015-11-24 |
| NCT01234766 |
Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT01234766 |
Active, not recruiting |
Dartmouth-Hitchcock Medical Center |
2014-06-30 |
| NCT01233921 |
Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT01233921 |
Completed |
Fred Hutchinson Cancer Research Center |
2012-07-31 |
| NCT01231919 |
MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia |
https://ClinicalTrials.gov/show/NCT01231919 |
Completed |
National Cancer Institute (NCI) |
2013-04-30 |
| NCT01216683 |
Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT01216683 |
Active, not recruiting |
Eastern Cooperative Oncology Group |
2020-06-01 |
| NCT01193842 |
Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas |
https://ClinicalTrials.gov/show/NCT01193842 |
Active, not recruiting |
National Cancer Institute (NCI) |
2016-11-12 |
| NCT01190449 |
Ofatumumab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01190449 |
Active, not recruiting |
Alliance for Clinical Trials in Oncology |
2015-03-31 |
| NCT01177371 |
High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01177371 |
Completed |
Case Comprehensive Cancer Center |
2000-02-29 |
| NCT01158274 |
RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors |
https://ClinicalTrials.gov/show/NCT01158274 |
Completed |
National Cancer Institute (NCI) |
2012-08-31 |
| NCT01145495 |
Lenalidomide and Rituximab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01145495 |
Active, not recruiting |
National Cancer Institute (NCI) |
2012-12-31 |
| NCT01130194 |
Immunochemotherapy, Zevalin, and Bone Marrow Transplant for Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT01130194 |
Completed |
St. Louis University |
2012-06-30 |
| NCT01129193 |
AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma |
https://ClinicalTrials.gov/show/NCT01129193 |
Completed |
Ohio State University Comprehensive Cancer Center |
2017-01-07 |
| NCT01110135 |
Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT01110135 |
Completed |
University of Washington |
2013-11-30 |
| NCT01093586 |
Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01093586 |
Completed |
Case Comprehensive Cancer Center |
2015-12-31 |
| NCT01078142 |
Temsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01078142 |
Completed |
Johannes Gutenberg University Mainz |
2017-09-08 |
| NCT01075321 |
Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01075321 |
Active, not recruiting |
Mayo Clinic |
2015-02-28 |
| NCT01029366 |
CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy |
https://ClinicalTrials.gov/show/NCT01029366 |
Completed |
University of Pennsylvania |
2015-07-31 |
| NCT01022255 |
Autologous Vaccine for Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT01022255 |
Completed |
Icon Genetics GmbH |
2013-10-31 |
| NCT00930514 |
A Pharmacokinetic Study of Subcutaneous and Intravenous Rituximab in Participants With Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT00930514 |
Completed |
Hoffmann-La Roche |
2013-07-31 |
| NCT00918333 |
Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT00918333 |
Completed |
Mayo Clinic |
2015-12-01 |
| NCT00912223 |
Blood Stem Cell Transplant With Low Dose Chemotherapy for Relapsed Follicular Non-Hodgkin’s Lymphoma (BMT CTN 0701) |
https://ClinicalTrials.gov/show/NCT00912223 |
Completed |
Medical College of Wisconsin |
2014-11-30 |
| NCT00904722 |
Monoclonal Antibody CT-011 in Combination With Rituximab in Patients With Relapsed Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT00904722 |
Completed |
M.D. Anderson Cancer Center |
2015-04-30 |
| NCT00891072 |
Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery |
https://ClinicalTrials.gov/show/NCT00891072 |
Completed |
National Cancer Institute (NCI) |
2011-04-30 |
| NCT00890747 |
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy |
https://ClinicalTrials.gov/show/NCT00890747 |
Completed |
National Cancer Institute (NCI) |
2011-05-31 |
| NCT00875056 |
Study of Vorinostat (MK0683) With Follicular Lymphoma (FL), Other Indolent B-cell Non-Hodgkin’s Lymphoma (B-NHL) or Mantle Cell Lymphoma (MCL) Patients (MK-0683-103) |
https://ClinicalTrials.gov/show/NCT00875056 |
Completed |
Merck Sharp & Dohme Corp. |
2011-02-25 |
| NCT00867529 |
Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00867529 |
Completed |
Fred Hutchinson Cancer Research Center |
2015-03-31 |
| NCT00864227 |
Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604) |
https://ClinicalTrials.gov/show/NCT00864227 |
Completed |
Medical College of Wisconsin |
2011-04-30 |
| NCT00856388 |
Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders |
https://ClinicalTrials.gov/show/NCT00856388 |
Completed |
Roswell Park Cancer Institute |
2012-08-09 |
| NCT00856245 |
Evaluate Rituximab in Obtaining PCR (Polymerase Chain Reaction) Negative Leukapheresis Product in Patients With Relapsed Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT00856245 |
Completed |
University of Kansas Medical Center |
2015-07-31 |
| NCT00849147 |
Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603) |
https://ClinicalTrials.gov/show/NCT00849147 |
Completed |
Medical College of Wisconsin |
2011-06-30 |
| NCT02278796 |
A Trial Comparing the Two High-dose Chemotherapies BeEAM and BEAM Given Before Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients (BEB-trial) |
https://ClinicalTrials.gov/show/NCT02278796 |
Active, not recruiting |
University Hospital Inselspital, Berne |
2018-11-28 |
| NCT00825149 |
A Study of Obinutuzumab in Combination With Chemotherapy in Participants With CD20+ B-Cell Follicular Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00825149 |
Completed |
Hoffmann-La Roche |
2015-11-30 |
| NCT03585725 |
A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03585725 |
Recruiting |
Weill Medical College of Cornell University |
2020-06-30 |
| NCT02809053 |
A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients With Low Tumor Burden Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT02809053 |
Active, not recruiting |
Archigen Biotech Limited |
2020-02-29 |
| NCT01427881 |
Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT01427881 |
Completed |
Fred Hutchinson Cancer Research Center |
2014-06-30 |
| NCT03460977 |
PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT03460977 |
Recruiting |
Pfizer |
2023-03-31 |
| NCT03332017 |
A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT03332017 |
Recruiting |
BeiGene |
2021-07-31 |
| NCT02451111 |
Rituximab With or Without Ibrutinib for Patients With Advanced Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT02451111 |
Active, not recruiting |
Swiss Group for Clinical Cancer Research |
2022-12-31 |
| NCT01849263 |
Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT01849263 |
Active, not recruiting |
National Cancer Institute (NCI) |
2016-06-03 |
| NCT00801281 |
First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance. |
https://ClinicalTrials.gov/show/NCT00801281 |
Completed |
Polish Lymphoma Research Group |
2017-06-25 |
| NCT03210662 |
Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT03210662 |
Recruiting |
M.D. Anderson Cancer Center |
2020-11-30 |
| NCT04224493 |
Study in Subjects With Relapsed/Refractory Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT04224493 |
Recruiting |
Epizyme, Inc. |
2022-06-30 |
| NCT03890289 |
Idelalisib+Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT03890289 |
Recruiting |
Fondazione Italiana Linfomi ONLUS |
2021-10-18 |
| NCT02260804 |
To Compare Efficacy and Safety Between CT-P10 and Rituxan in Patients With Low Tumour Burden Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT02260804 |
Active, not recruiting |
Celltrion |
2018-01-31 |
| NCT01476787 |
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT01476787 |
Active, not recruiting |
Celgene |
2024-06-01 |
| NCT03976102 |
Compare the Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera® in LTB Follicular Lymphoma (FLINTER) |
https://ClinicalTrials.gov/show/NCT03976102 |
Recruiting |
Dr. Reddy’s Laboratories Limited |
2020-09-01 |
| NCT01208896 |
Allogeneic Hematopoietic Stem Cell Transplantation After Reduced-intensity Conditioning for Relapsed Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT01208896 |
Completed |
University Hospital, Bordeaux |
2017-09-28 |
| NCT00794638 |
A Phase I Clinical Trial to Assess the Safety of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00794638 |
Completed |
SymBio Pharmaceuticals |
2010-03-31 |
| NCT00783367 |
Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas |
https://ClinicalTrials.gov/show/NCT00783367 |
Active, not recruiting |
Abramson Cancer Center of the University of Pennsylvania |
2012-11-14 |
| NCT00770224 |
S0801 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT00770224 |
Completed |
Southwest Oncology Group |
2017-04-30 |
| NCT00769288 |
FAU in Treating Patients With Advanced Solid Tumors or Lymphoma |
https://ClinicalTrials.gov/show/NCT00769288 |
Completed |
National Cancer Institute (NCI) |
2013-12-31 |
| NCT00742144 |
Ofatumumab in Japanese Patients With CD20 Positive Follicular Lymphoma or Chronic Lymphocytic Leukemia |
https://ClinicalTrials.gov/show/NCT00742144 |
Completed |
GlaxoSmithKline |
2009-11-18 |
| NCT00723099 |
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00723099 |
Completed |
Fred Hutchinson Cancer Research Center |
2018-07-31 |
| NCT00720135 |
Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT00720135 |
Completed |
City of Hope Medical Center |
2014-07-31 |
| NCT00719472 |
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin’s Lymphoma (RATE) |
https://ClinicalTrials.gov/show/NCT00719472 |
Completed |
Genentech, Inc. |
2011-05-31 |
| NCT00715208 |
Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT00715208 |
Completed |
Millennium Pharmaceuticals, Inc. |
2011-02-28 |
| NCT00711828 |
Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00711828 |
Completed |
Mayo Clinic |
2013-11-30 |
| NCT00696735 |
High-Dose Therapy Treatment in Patients With Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT00696735 |
Completed |
French Innovative Leukemia Organisation |
2003-05-31 |
| NCT00695786 |
Lenalidomide in Combination With Rituximab in Treating Participants With Stage III/IV Indolent Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT00695786 |
Active, not recruiting |
M.D. Anderson Cancer Center |
2020-06-30 |
| NCT00636792 |
A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT00636792 |
Completed |
Millennium Pharmaceuticals, Inc. |
2010-05-31 |
| NCT00634179 |
A Phase I/II Trial of VR-CHOP in Lymphoma Patients |
https://ClinicalTrials.gov/show/NCT00634179 |
Completed |
Emory University |
2015-11-30 |
| NCT00621452 |
Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT00621452 |
Completed |
Fred Hutchinson Cancer Research Center |
2014-01-31 |
| NCT00608361 |
Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery |
https://ClinicalTrials.gov/show/NCT00608361 |
Completed |
National Cancer Institute (NCI) |
2014-08-31 |
| NCT00601718 |
Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00601718 |
Completed |
University of Washington |
2010-06-30 |
| NCT00574730 |
CHOP/Rituximab Followed by Maintenance PEG Intron in Treatment of Indolent/Follicular Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00574730 |
Completed |
University of Nebraska |
2005-08-31 |
| NCT00553501 |
Epratuzumab and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT00553501 |
Completed |
Alliance for Clinical Trials in Oncology |
2010-07-31 |
| NCT00546793 |
Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL |
https://ClinicalTrials.gov/show/NCT00546793 |
Completed |
Immunomedics, Inc. |
2013-03-31 |
| NCT00536601 |
High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors |
https://ClinicalTrials.gov/show/NCT00536601 |
Completed |
Roswell Park Cancer Institute |
2018-07-09 |
| NCT00530140 |
Idiotypic Vaccination for Follicular Lymphoma Patients |
https://ClinicalTrials.gov/show/NCT00530140 |
Recruiting |
Clinica Universidad de Navarra, Universidad de Navarra |
2013-09-30 |
| NCT00509184 |
Rituximab and Involved Field Radiotherapy in Early Stage Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT00509184 |
Completed |
Heidelberg University |
2013-04-30 |
| NCT00499811 |
Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction |
https://ClinicalTrials.gov/show/NCT00499811 |
Completed |
National Cancer Institute (NCI) |
2011-08-31 |
| NCT00494780 |
Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide,Doxorubicin, Vincristine, Predisolone) in Follicular Lymphoma (FL) Patients |
https://ClinicalTrials.gov/show/NCT00494780 |
Completed |
GlaxoSmithKline |
2009-04-30 |
| NCT00489203 |
Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00489203 |
Completed |
Fred Hutchinson Cancer Research Center |
2010-11-30 |
| NCT00487305 |
Vaccination for the Treatment of Previously Untreated or Relapsed Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT00487305 |
Active, not recruiting |
Dana-Farber Cancer Institute |
2020-08-31 |
| NCT00475644 |
A Study of Enzastaurin in Participants With Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT00475644 |
Completed |
Eli Lilly and Company |
2012-04-30 |
| NCT00458731 |
Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma |
https://ClinicalTrials.gov/show/NCT00458731 |
Completed |
National Cancer Institute (NCI) |
2013-12-31 |
| NCT00440388 |
Safety & Efficacy Study of AT-101 in Combination w/ Rituximab in Previously Untreated Grade I-II Follicular Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00440388 |
Completed |
Ascenta Therapeutics |
2008-11-30 |
| NCT00438880 |
Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT00438880 |
Completed |
Mayo Clinic |
2010-10-31 |
| NCT00428142 |
Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00428142 |
Completed |
Canadian Cancer Trials Group |
2011-04-30 |
| NCT00427856 |
Safety and Efficacy of Single Agent Obatoclax Mesylate (GX15-070MS) Followed by a Combination With Rituximab for Previously-untreated Follicular Lymphoma (FL) |
https://ClinicalTrials.gov/show/NCT00427856 |
Completed |
Teva Pharmaceutical Industries |
2009-02-28 |
| NCT00408681 |
Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT00408681 |
Completed |
Fred Hutchinson Cancer Research Center |
2010-11-30 |
| NCT00406809 |
A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies |
https://ClinicalTrials.gov/show/NCT00406809 |
Completed |
AbbVie |
2016-10-31 |
| NCT00394836 |
HuMax-CD20 i(Ofatumumab) n Follicular Lymphoma (FL) Patients Refractory to Rituximab |
https://ClinicalTrials.gov/show/NCT00394836 |
Completed |
GlaxoSmithKline |
2009-04-30 |
| NCT00393107 |
Safety and Efficacy of Fludarabine and Cyclophosphamide + Rituximab |
https://ClinicalTrials.gov/show/NCT00393107 |
Completed |
Gruppo Italiano Studio Linfomi |
NA |
| NCT00799461 |
Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications |
https://ClinicalTrials.gov/show/NCT00799461 |
Completed |
Fred Hutchinson Cancer Research Center |
2011-11-30 |
| NCT00366275 |
Immunochemotherapy, in Vivo Purging, PBSC Mobilization and Autotransplant in Relapsed or Refractory Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT00366275 |
Completed |
IRCCS Policlinico S. Matteo |
2007-01-31 |
| NCT00348985 |
PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas |
https://ClinicalTrials.gov/show/NCT00348985 |
Completed |
National Cancer Institute (NCI) |
2010-01-31 |
| NCT00343798 |
A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00343798 |
Completed |
Fred Hutchinson Cancer Research Center |
2013-07-31 |
| NCT00317096 |
FCM Versus R-FCM Followed by R-Maintenance or Observation Only |
https://ClinicalTrials.gov/show/NCT00317096 |
Active, not recruiting |
Ludwig-Maximilians - University of Munich |
2001-06-30 |
| NCT00315731 |
A Study Of Pharmacokinetics, Whole Body And Organ Dosimetry, And Biodistribution Of Fission-Derived Iodine I 131 Tositumomab (BEXXAR®) For Patients With Previously Untreated Or Relapsed Follicular Or Transformed Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00315731 |
Completed |
GlaxoSmithKline |
2006-12-04 |
| NCT00293345 |
3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma |
https://ClinicalTrials.gov/show/NCT00293345 |
Completed |
National Cancer Institute (NCI) |
2012-10-31 |
| NCT00290511 |
Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT00290511 |
Active, not recruiting |
M.D. Anderson Cancer Center |
2020-08-24 |
| NCT00290472 |
CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin’s Lymphoma or Chronic Lymphocytic Leukemia |
https://ClinicalTrials.gov/show/NCT00290472 |
Completed |
National Cancer Institute (NCI) |
2010-04-30 |
| NCT00275431 |
Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies |
https://ClinicalTrials.gov/show/NCT00275431 |
Completed |
Ascenta Therapeutics |
2008-12-31 |
| NCT00275080 |
Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin’s Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia |
https://ClinicalTrials.gov/show/NCT00275080 |
Completed |
National Cancer Institute (NCI) |
2009-11-30 |
| NCT00268983 |
Comparison Of Rituximab Versus Tositumomab and Iodine I 131 Tositumomab (BEXXAR® Therapeutic Regimen) For Patients With Relapsed Follicular Non-Hodgkins Lymphoma |
https://ClinicalTrials.gov/show/NCT00268983 |
Completed |
GlaxoSmithKline |
2009-09-30 |
| NCT00253630 |
Vorinostat in Treating Patients With Low-Grade Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00253630 |
Completed |
National Cancer Institute (NCI) |
2016-05-31 |
| NCT00244855 |
Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT00244855 |
Completed |
Fred Hutchinson Cancer Research Center |
2008-12-31 |
| NCT00238238 |
Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin’s Lymphoma That is Not Refractory to Rituximab |
https://ClinicalTrials.gov/show/NCT00238238 |
Completed |
Alliance for Clinical Trials in Oncology |
2012-06-30 |
| NCT00201877 |
Velcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00201877 |
Completed |
Ohio State University Comprehensive Cancer Center |
2009-06-30 |
| NCT00193492 |
A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00193492 |
Completed |
SCRI Development Innovations, LLC |
2013-03-31 |
| NCT00193440 |
Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low Grade Follicular Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00193440 |
Completed |
SCRI Development Innovations, LLC |
2004-04-30 |
| NCT00185393 |
Treatment With [90]Y-Ibritumomab Tiuxetan Versus no Treatment in Patients With Follicular Non Hodgkin Lymphoma (Stage III or IV) Having Achieved a Partial or Complete Remission After First Line Chemotherapy |
https://ClinicalTrials.gov/show/NCT00185393 |
Completed |
Bayer |
NA |
| NCT00177554 |
Phase II Trial of CHOP-R Followed by Zevalin and Rituxan in Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT00177554 |
Completed |
University of Pittsburgh |
2007-05-31 |
| NCT00169208 |
Fludarabine, Mitoxantrone and Rituximab in Relapsed or Primary Failing Advanced Follicular Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00169208 |
Completed |
Lymphoma Study Association |
2006-12-31 |
| NCT00140582 |
Primary Rituximab and Maintenance |
https://ClinicalTrials.gov/show/NCT00140582 |
Completed |
Lymphoma Study Association |
2007-05-31 |
| NCT00140569 |
Randomized Study for Patients With Follicular Lymphoma Needing Treatment |
https://ClinicalTrials.gov/show/NCT00140569 |
Completed |
Lymphoma Study Association |
NA |
| NCT00136552 |
Study for Newly Diagnosed Follicular Lymphoma Patients With a Large Tumor Burden |
https://ClinicalTrials.gov/show/NCT00136552 |
Completed |
Lymphoma Study Association |
NA |
| NCT00119392 |
Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00119392 |
Completed |
Fred Hutchinson Cancer Research Center |
2009-07-31 |
| NCT00118352 |
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00118352 |
Completed |
Fred Hutchinson Cancer Research Center |
2010-07-31 |
| NCT00118170 |
Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin’s Lymphoma With or Without Impaired Liver or Kidney Function |
https://ClinicalTrials.gov/show/NCT00118170 |
Completed |
National Cancer Institute (NCI) |
2007-05-31 |
| NCT00115700 |
Radiotherapy Versus Radiotherapy Plus Chemotherapy in Early Stage Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT00115700 |
Active, not recruiting |
Trans-Tasman Radiation Oncology Group (TROG) |
2021-12-31 |
| NCT00112593 |
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer |
https://ClinicalTrials.gov/show/NCT00112593 |
Completed |
Fred Hutchinson Cancer Research Center |
2014-11-30 |
| NCT00110071 |
Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00110071 |
Completed |
Fred Hutchinson Cancer Research Center |
2011-06-30 |
| NCT00105001 |
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00105001 |
Completed |
Fred Hutchinson Cancer Research Center |
2011-05-31 |
| NCT00098891 |
MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas |
https://ClinicalTrials.gov/show/NCT00098891 |
Completed |
National Cancer Institute (NCI) |
2008-03-31 |
| NCT00089271 |
17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas |
https://ClinicalTrials.gov/show/NCT00089271 |
Completed |
National Cancer Institute (NCI) |
2010-06-30 |
| NCT00089011 |
Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00089011 |
Completed |
Fred Hutchinson Cancer Research Center |
2014-03-31 |
| NCT00003196 |
Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT00003196 |
Completed |
Fred Hutchinson Cancer Research Center |
2002-04-30 |
| NCT00006251 |
Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer |
https://ClinicalTrials.gov/show/NCT00006251 |
Completed |
Fred Hutchinson Cancer Research Center |
2005-09-30 |
| NCT00082888 |
Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma |
https://ClinicalTrials.gov/show/NCT00082888 |
Completed |
National Cancer Institute (NCI) |
2009-05-20 |
| NCT00082784 |
Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms |
https://ClinicalTrials.gov/show/NCT00082784 |
Completed |
National Cancer Institute (NCI) |
2012-10-31 |
| NCT00081809 |
A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent Lymphoma |
https://ClinicalTrials.gov/show/NCT00081809 |
Completed |
Agenus Inc. |
2005-06-30 |
| NCT00005799 |
Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer |
https://ClinicalTrials.gov/show/NCT00005799 |
Completed |
Fred Hutchinson Cancer Research Center |
2002-07-31 |
| NCT00078858 |
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT00078858 |
Completed |
Fred Hutchinson Cancer Research Center |
2006-01-31 |
| NCT00077155 |
Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma |
https://ClinicalTrials.gov/show/NCT00077155 |
Completed |
National Cancer Institute (NCI) |
2010-06-30 |
| NCT00073918 |
Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00073918 |
Completed |
Fred Hutchinson Cancer Research Center |
2011-10-02 |
| NCT00072514 |
Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies |
https://ClinicalTrials.gov/show/NCT00072514 |
Completed |
Fred Hutchinson Cancer Research Center |
2008-07-31 |
| NCT00068315 |
Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin’s Lymphoma or Chronic Lymphocytic Leukemia |
https://ClinicalTrials.gov/show/NCT00068315 |
Completed |
National Cancer Institute (NCI) |
2008-12-31 |
| NCT00003210 |
Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin’s Lymphoma or Hodgkin’s Disease |
https://ClinicalTrials.gov/show/NCT00003210 |
Completed |
National Cancer Institute (NCI) |
2003-11-30 |
| NCT00020462 |
Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III, Stage IV, or Recurrent Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT00020462 |
Completed |
National Cancer Institute (NCI) |
NA |
| NCT00062894 |
Study of Untreated or Transformed Follicular Non-Hodgkin’s Lymphoma With Fission-Derived Iodine I 131 Tositumomab |
https://ClinicalTrials.gov/show/NCT00062894 |
Completed |
GlaxoSmithKline |
NA |
| NCT00795769 |
Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT00795769 |
Completed |
Fred Hutchinson Cancer Research Center |
2009-06-09 |
| NCT00060684 |
Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00060684 |
Completed |
CTI BioPharma |
2005-01-31 |
| NCT00058305 |
Bryostatin 1 Plus Vincristine in Treating Patients With Progressive or Relapsed Non-Hodgkin’s Lymphoma After Bone Marrow or Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT00058305 |
Completed |
National Cancer Institute (NCI) |
2007-12-31 |
| NCT00058227 |
Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00058227 |
Completed |
National Cancer Institute (NCI) |
2009-02-28 |
| NCT00054639 |
Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT00054639 |
Completed |
National Cancer Institute (NCI) |
2010-01-31 |
| NCT00054483 |
Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction |
https://ClinicalTrials.gov/show/NCT00054483 |
Completed |
National Cancer Institute (NCI) |
2009-09-30 |
| NCT00049504 |
Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00049504 |
Completed |
Fred Hutchinson Cancer Research Center |
2011-03-31 |
| NCT00040846 |
Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT00040846 |
Completed |
Fred Hutchinson Cancer Research Center |
2009-12-31 |
| NCT00026182 |
Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00026182 |
Completed |
National Cancer Institute (NCI) |
2005-02-28 |
| NCT00025415 |
Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction |
https://ClinicalTrials.gov/show/NCT00025415 |
Completed |
National Cancer Institute (NCI) |
2005-01-31 |
| NCT00022581 |
Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00022581 |
Completed |
National Cancer Institute (NCI) |
2004-12-31 |
| NCT00017381 |
Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00017381 |
Completed |
National Cancer Institute (NCI) |
2007-12-31 |
| NCT00014235 |
Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00014235 |
Completed |
Fred Hutchinson Cancer Research Center |
2005-02-28 |
| NCT00010192 |
Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00010192 |
Completed |
National Cancer Institute (NCI) |
2003-01-31 |
| NCT00006473 |
Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00006473 |
Completed |
National Cancer Institute (NCI) |
2006-02-28 |
| NCT00004241 |
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma |
https://ClinicalTrials.gov/show/NCT00004241 |
Completed |
National Cancer Institute (NCI) |
2006-05-31 |
| NCT00003970 |
Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma |
https://ClinicalTrials.gov/show/NCT00003970 |
Completed |
National Cancer Institute (NCI) |
2003-10-31 |
| NCT00003204 |
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Low-Grade Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00003204 |
Completed |
National Cancer Institute (NCI) |
2006-05-31 |
| NCT00002649 |
Interleukin-2 or Observation Following Radiation Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00002649 |
Completed |
National Cancer Institute (NCI) |
2006-11-30 |
| NCT00023764 |
Bortezomib in Treating Patients With Lymphoproliferative Disorders |
https://ClinicalTrials.gov/show/NCT00023764 |
Completed |
National Cancer Institute (NCI) |
2009-03-31 |
| NCT00001572 |
Vaccination of Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype |
https://ClinicalTrials.gov/show/NCT00001572 |
Completed |
National Institutes of Health Clinical Center (CC) |
1999-07-31 |
| NCT00001512 |
Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines |
https://ClinicalTrials.gov/show/NCT00001512 |
Completed |
National Institutes of Health Clinical Center (CC) |
2010-03-05 |